This is an old revision of this page, as edited by Alakey(talk | contribs) at 23:54, 30 January 2017(→External links: Adding link to BTLA gene details page and display in UCSC genome browser.). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.
Revision as of 23:54, 30 January 2017 by Alakey(talk | contribs)(→External links: Adding link to BTLA gene details page and display in UCSC genome browser.)
BTLA expression is induced during activation of T cells, and BTLA remains expressed on Th1 cells but not Th2 cells. Like PD1 and CTLA4, BTLA interacts with a B7 homolog, B7H4.[6] However, unlike PD-1 and CTLA-4, BTLA displays T-Cell inhibition via interaction with tumor necrosis family receptors (TNF-R), not just the B7 family of cell surface receptors. BTLA is a ligand for tumour necrosis factor (receptor) superfamily, member 14 (TNFRSF14), also known as herpes virus entry mediator (HVEM). BTLA-HVEM complexes negatively regulate T-cell immune responses.
Clinical significance
BTLA activation inhibits the function of human CD8+ cancer-specific T cells.[7]
^"Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
^"Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
^Watanabe N, Gavrieli M, Sedy JR, Yang J, Fallarino F, Loftin SK, Hurchla MA, Zimmerman N, Sim J, Zang X, Murphy TL, Russell JH, Allison JP, Murphy KM (Jun 2003). "BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1". Nat Immunol. 4 (7): 670–9. doi:10.1038/ni944. PMID12796776.